Clinical Measures of Islet Function: Usefulness to Characterize Defects in Diabetes

被引:21
作者
Ahren, Bo [1 ]
Pratley, Richard E. [2 ]
Soubt, Mazin [3 ]
Dunning, Beth E. [4 ]
Foley, James E. [5 ]
机构
[1] Lund Univ, Lund, Sweden
[2] Univ Vermont, Coll Med, Burlington, VT USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] PharmaWrite LLC, Princeton, NJ USA
[5] Novartis Pharmaceut, E Hanover, NJ USA
关键词
D O I
10.2174/157339908784220714
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In healthy individuals, the ability of the pancreatic islets to sense and respond appropriately to changes in plasma glucose levels maintains plasma glucose levels within a narrow range despite broad fluctuations in nutrient intake and variable "demand" for insulin imposed by changes in insulin sensitivity. This ability of the pancreatic islets is lost in type 2 diabetes (T2DM). For studies on the pathophysiology of T2DM, methods for analyzing islet function are therefore required. Many methods of varying degrees of complexity have been developed and used to measure pancreatic - cell function in humans and to characterize the defects existing in patients with T2DM or precursors thereof (impaired fasting glucose [IFG] and impaired glucose tolerance [IGT]). Significant, although perhaps less progress has been made toward development of methods to characterize - cell function. This work presents an overview of clinical measures of islet function, from simple static measures such as HOMA- to the more complex dynamic measures such as those utilizing stepped hyperglycemic clamps and acute administration of arginine to obtain more detailed information regarding the interaction of glucose and non- glucose secretagogues. We emphazise the need for accurate measures of - cell function, and we discuss the strengths and limitations of the various methods, highlighting the many aspects of both - and - cell function that become impaired during development of T2DM.
引用
收藏
页码:129 / 145
页数:17
相关论文
共 60 条
[1]   Glucagon secretion in relation to insulin sensitivity in healthy subjects [J].
Ahrén, B .
DIABETOLOGIA, 2006, 49 (01) :117-122
[2]   Islet adaptation to insulin resistance:: mechanisms and implications for intervention [J].
Ahrén, B ;
Pacini, G .
DIABETES OBESITY & METABOLISM, 2005, 7 (01) :2-8
[3]   GLUCAGON IMMUNOREACTIVITY IN PLASMA FROM NORMAL AND DYSTROPHIC MICE [J].
AHREN, B ;
LUNDQUIST, I .
DIABETOLOGIA, 1982, 22 (04) :258-263
[4]   Impaired adaptation of first-phase insulin secretion in postmenopausal women with glucose intolerance [J].
Ahren, B ;
Pacini, G .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1997, 273 (04) :E701-E707
[5]   IMMUNOREACTIVE GLUCAGON (IRG) RESPONSES TO INTRAVENOUS GLUCOSE IN PREDIABETES AND DIABETES AMONG PIMA INDIANS AND NORMAL CAUCASIANS [J].
ARONOFF, SL ;
BENNETT, PH ;
UNGER, RH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1977, 44 (05) :968-972
[6]   SIGNIFICANCE OF BASAL INSULIN LEVELS IN EVALUATION OF INSULIN RESPONSE TO GLUCOSE IN DIABETIC AND NONDIABETIC SUBJECTS [J].
BAGDADE, JD ;
BIERMAN, EL ;
PORTE, D .
JOURNAL OF CLINICAL INVESTIGATION, 1967, 46 (10) :1549-+
[7]   BASAL AND STIMULATED INSULIN LEVELS - COMPARISON OF INSULINOGENIC EFFECTS OF ORAL GLUCOSE AND INTRAVENOUS TOLBUTAMIDE IN NONDIABETIC AND DIABETIC SUBJECTS [J].
BAGDADE, JD ;
BIERMAN, EL ;
PORTE, D .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1971, 20 (11) :1000-+
[8]   PHYSIOLOGIC EVALUATION OF FACTORS CONTROLLING GLUCOSE-TOLERANCE IN MAN - MEASUREMENT OF INSULIN SENSITIVITY AND BETA-CELL GLUCOSE SENSITIVITY FROM THE RESPONSE TO INTRAVENOUS GLUCOSE [J].
BERGMAN, RN ;
PHILLIPS, LS ;
COBELLI, C .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (06) :1456-1467
[9]  
BOLLI GB, 1984, J CLIN INVEST, V73, P1532, DOI 10.1172/JCI111359
[10]   Altered homeostatic adaptation of first- and second-phase β-cell secretion in the offspring of patients with type 2 diabetes -: Studies with a minimal model to assess β-cell function [J].
Bonadonna, RC ;
Stumvoll, M ;
Fritsche, A ;
Muggeo, M ;
Häring, H ;
Bonora, E ;
van Haeften, TW .
DIABETES, 2003, 52 (02) :470-480